XML 58 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Balance Sheet Components - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Milestone
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Schedule of Available-for-sale Securities [Line Items]          
Cash and cash equivalents $ 74,587,000   $ 74,587,000   $ 89,258,000
Contractual maturities of available-for-sale investments     1 year    
Other-than-temporary impairment loss 0 $ 0 $ 0 $ 0  
Provision to write-down excess and obsolete inventory 0   $ 0    
Number of regulatory milestones | Milestone     2    
Unbilled contract assets 180,000,000   $ 180,000,000   0
Building shell cost 140,786,000   140,786,000   192,397,000
Accumulated depreciation 95,921,000   95,921,000   65,199,000
Building shell [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Building shell cost 0   0   53,880,000
Building [Member] | Build to suit arrangements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Accumulated depreciation         13,500,000
Leasehold improvements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Building shell cost 101,250,000   101,250,000   101,200,000
Leasehold improvements [Member] | Accounting standards update 2016-02 [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Accumulated depreciation 38,900,000   38,900,000    
Europe [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Unbilled contract assets 130,000,000.0   130,000,000.0    
Astellas Agreement [Member] | Europe [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Unbilled contract assets 130,000,000.0   130,000,000.0    
AstraZeneca Agreements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Unbilled contract assets 50,000,000.0   50,000,000.0    
AstraZeneca Agreements [Member] | U.S./RoW [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Unbilled contract assets 50,000,000.0   50,000,000.0    
Foreign subsidiaries [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Cash and cash equivalents $ 26,000,000.0   $ 26,000,000.0   $ 21,900,000